Molecular Med TRI-CON 2013
February 11-15 • Moscone North Convention Center • San Francisco, CA

Conference Programs

Mastering Medicinal Chemistry
In an Era of Tough Targets

Cancer Biologics
Approaches Changing the Treatment of Cancer

Clinical and Translational Science
Strategies to Accelerate and De-Risk Clinical Development

Featured Presentations

Using Synthetic Chemistry to Answer the Challenge of Increasing Molecular Complexity in Small Molecule Drug Discovery
Simon Bailey, Ph.D., Senior Director, Worldwide Medicinal Chemistry Oncology, Pfizer

The Yin and Yang of Personalized Medicine
Stefan Scherer, M.D., Ph.D., Head, Global Biomarkers, PD, Genentech, Inc.

Empowered Antibodies for Cancer Therapy
Peter Senter, Ph.D., Vice President, Chemistry, Seattle Genetics, Inc.

Register by January 18, 2013
Save up to $200!

Premier Sponsors:

Organized by Cambridge Healthtech Institute

TriConference.com/Therapeutics
Personalized Oncology – Fulfilling the Promise for Today’s Patients

In honor of the 20th anniversary of the Molecular Medicine Tri-Conference, CHI and Cancer Commons will present a plenary panel on Personalized Oncology. Innovations such as NGS and The Cancer Genome Atlas have revealed that cancer comprises hundreds of distinct molecular diseases. Early clinical successes with targeted therapies suggest that cancer might one day be managed as a chronic disease using an evolving cocktail of drugs. Representing all five conference channels, Diagnostics, Therapeutics, Clinical, Informatics, and Cancer, a panel of experts will lead a highly interactive exploration of what it will take to realize this vision in the near future.

Topics for discussion include:

- Scientific approaches to treating cancer, involving deep molecular profiling and pathway analysis of individual tumors to design custom treatments, and then monitoring the tumor’s response to therapy using sequential biopsies and CTCs.
- Open science initiatives to rapidly learn and refine the clinically actionable, molecular subtypes of cancer and how to treat them.
- New models of translational research that can slash the time and cost of developing highly targeted agents for rare subtypes.
- Efficient systems to enable patients affordable investigational drugs for testing in small proof-of-concept studies.
- Complementary computational approaches to identifying cancer pathways, targets, and subtypes.
- Pragmatic approaches for capturing treatment and outcomes data from every cancer patient, to validate and extend the knowledge of molecular subtypes and treatments.
- The industry ecosystem and what’s needed to deliver personalized oncology services at scale.

Moderator: Marty Tenenbaum, Ph.D., Founder and Chairman, Cancer Commons; Prominent AI Researcher; Cancer Survivor

Tony Blau, M.D., Professor, Department of Medicine/Hematology and Adjunct Professor, Department of Genome Sciences, University of Washington; Attending Physician, Seattle Cancer Care Alliance; Co-Director, Institute for Stem Cell and Regenerative Medicine, University of Washington and the Program for Stem and Progenitor Cell Biology at the UW/FHRC Cancer Consortium; Founder and Scientific Officer, Partners in Personal Oncology

Sarah Greene, Executive Director, Cancer Commons

Mikhail Gishizky, Ph.D., CSO, Entelos Inc

Jane Reese-Coulbourne, MS, ChE, Executive Director, Reagan-Udall Foundation for the FDA; Former Board Chair, Lung Cancer Alliance; Cancer Survivor

Anil Sethi, CEO, Pinch Bio; HL7 Pioneer and Health Informatics Entrepreneur

Joshua Stuart, Ph.D., Associate Professor, Department of Biomolecular Engineering, University of California Santa Cruz

Plenary Keynote Panel: Emerging Technologies & Industry Perspectives

This session features a series of presentations on emerging and hot technologies in diagnostics, drug discovery & development, informatics, and oncology. Interactive Q&A discussion with the audience will be included.

- Moderator: To be Announced
- Gregory Parekh, Ph.D., CEO, Biocartis
- Kevin Bobofchak, Ph.D., Pathway Studio Product Manager, Elsevier
- Jeremy Bridge-Cook, Ph.D., Senior Vice President, Research & Development, Luminex Corporation
- Panelist to be Announced, Remedy Informatics
- Harry Glorikian, Managing Partner, Scientia Advisors, LLC
- Lynn R. Zieske, Ph.D., Vice President, Commercial Solutions, Singulex, Inc.

Co-located Event

BayBio Entrepreneur & Investor Roundtables

February 14, 2013, 4:00-7:00 pm

Connect with corporate venture, angel investors and VCs

www.baybioundroundtables.com
Conference Programs:
Feb 13-15

Diagnostics Channel
Molecular Diagnostics
Personalized Diagnostics
Cancer Molecular Markers
Circulating Tumor Cells
Digital Pathology – NEW
Companion Diagnostics – NEW

Therapeutics Channel
Mastering Medicinal Chemistry
Cancer Biologics
Clinical and Translational Science

Clinical Channel
Oncology Clinical Trials
Clinical and Translational Science
Clinical Sequencing – NEW

Informatics Channel
Bioinformatics in the Genome Era
Integrated R&D Informatics and Knowledge Management

Cancer Channel
Cancer Molecular Markers
Circulating Tumor Cells
Predictive Pre-Clinical Models in Oncology – NEW
Oncology Clinical Trials
Cancer Biologics

Symposia*:
Feb 11-12
Targeting Cancer Stem Cells
Genomics in Medicine – NEW
Point-of-Care Diagnostics
Quantitative Real-Time PCR – NEW
Next Generation Pathology

Partnering Forum*:
Feb 11-12
Emerging Molecular Diagnostics

Short Courses*:
Feb 12
1:30-4:30pm
SC1 Identification & Characterization of Cancer Stem Cells
SC2 Commercialization Boot Camp: Manual for Success in the Molecular Diagnostics Marketplace
SC3 NGS Data and the Cloud
SC4 Best Practices in Personalized and Translational Medicine
SC5 Latest Advances in Molecular Pathology
SC6 Regulatory Approval of a Therapeutic & Companion Diagnostic: Nuts & Bolts
SC7 PCR Part I: qPCR in Molecular Diagnostics
SC8 Data Visualization
SC9 Methods for Synthesis & Screening of Macroyclic Compound Libraries
SC10 PCR Part II: Digital PCR Applications and Advances
SC11 Sample Prep and Biorepositories for Cancer Research
SC12 Next-Generation Sequencing in Molecular Pathology: Challenges and Applications
SC13 Strategies for Companion Diagnostics Development
SC14 Patient-Derived Cancer Tissue Xenograph Models
SC15 Microfluidics Technology and Market Trends
SC16 Open Cloud & Data Science

5:00-8:00pm (Dinner)
SC17 Open Cloud & Data Science

Recommended Programs:

Symposia
• Targeting Cancer Stem Cells
• Next-Generation Pathology

Short Courses
• Identification and Characterization of Cancer Stem Cells
• Best Practices in Personalized and Translational Medicine
• Regulatory Approval for a Therapeutic and a Diagnostic
• Regulatory Strategies for Cell Therapy

TRI-CON All Access Package
Get the best 5-day value! Our All Access Packages is a convenient, cost-effective way to attend each aspect of Molecular Med TRI-CON 2013. Package includes access to 1 Symposium or Partnering Forum, 2 Short Courses and 1 Conference Program.

*Separate reg required with a la carte pricing
WEDNESDAY, FEBRUARY 13

7:00 am Registration and Morning Coffee

Plenary Keynote Session

8:00 Plenary Keynote Presentation (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Increasing Complexity, Macrocycles, 3-D Structure, Shape & Chirality

11:00 Chairperson’s Opening Remarks
Nick Terrett, Ph.D., CSO, Ensemble Therapeutics Corp.

11:10 Opening Address: Using Synthetic Chemistry to Answer the Challenge of Increasing Molecular Complexity in Small Molecule Drug Discovery
Simon Bailey, Ph.D., Sr. Director, Worldwide Medicinal Chemistry Oncology, Pfizer

11:40 Beyond the Rule of Five – Novel Strategies for Accessing Macrocyclic Chemical Space
Keith James, President, Ferring Research Institute; Visiting Investigator, The Scripps Research Institute

12:10 pm Moving in New Circles – An Introduction to Macrocycles in Drug Discovery
Nick Terrett, Ph.D., CSO, Ensemble Therapeutics Corp.

12:40 Exploiting the Chemical Space of Macrolides as Promising Templates for New Drugs
Vesna Gabelica Markovic, Ph.D., Senior Director, Chemistry, Fidelta

1:45 20th Anniversary Cake in the Exhibit Hall with Poster Viewing

Next-Generation Payload Linker and Conjugation Technologies

2:15 Chairperson’s Remarks

2:20 Design of Novel Linkers, Payloads and Antibody-Drug Conjugates for the Treatment of Cancer
Christopher J. O’Donnell, Ph.D., Sr. Director, Oncology Medicinal Chemistry, Pfizer

2:50 Antibody-Drug Conjugates for the Treatment of Cancer
John Flygare, Ph.D., Senior Scientist, Discovery Chemistry, Genentech

3:20 Using Small Molecules to Engineer and Explore Human Immunity
David A. Spiegel, Ph.D., Associate Professor of Chemistry, Yale

3:50 Rationalization Non-Standard Interactions in Ligand Design: The Duality of Halogens
Chris Williams, Ph.D., Principal Scientist, Chemical Computing Group

4:20 Networking Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunities Available)

5:20 Breakout Discussions in the Exhibit Hall (See Web for Details)

6:20 Close of Day

THURSDAY, FEBRUARY 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Plenary Keynote Panel (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Increasing Complexity

10:40 Chairperson’s Remarks
Michael Foley, Ph.D., Director, Chemical Biology, Broad Institute

10:45 Membrane Permeability and Oral Bioavailability of Macrocycles
Matthew P. Jacobson, Ph.D., Professor, Pharmaceutical Chemistry, Department of Bioengineering and Therapeutic Science, University of California San Francisco

11:15 Synthetic Macrocycles: Leveraging Natures Design Strategy
Michael Foley, Ph.D., Director, Chemical Biology, Broad Institute

11:45 Molecular Complexity and Promiscuity
Frank Lovering, Ph.D., Principle Scientist II, Computational Chemistry, Pfizer

12:15 pm Knowledge Mining by Structure Search
Jinbo Lee, Ph.D., CSO, Scilligence Corporation

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

Hot Targets to Watch: Epigenetic Targets

1:40 Chairperson’s Remarks
Ed Olhava, Ph.D., Associate Director, Pre-Clinical Development, Epizyme, Inc.

1:45 Chemically Targeting the Histone Lysine Methyltransferase EZH2 (Enhancer of Zeste Homolog 2)
Sharad K. Verma, Ph.D., Investigator, Medicinal Chemistry, GlaxoSmithKline

2:15 Inhibition of BET Bromodomains for the Treatment of Cancer
Brian K. Albrecht, Ph.D., Sr. Dir., Medicinal Chemistry, Constellation Pharmaceuticals
In an Era of Tough Targets

**2:45 From Protein to Candidate: Discovery of EPZ-5676, A Potent and Selective Inhibitor of the Histone Methyltransferase DOT1L**
Ed Olhava, Ph.D., Associate Director, Pre-Clinical Development, Epizyme, Inc.

**3:15 Advances in the Treatment of Water Molecules for Assessing Druggability, Understanding SAR, and Computing Binding Energies**
Chris Higgs, Senior Applications Scientist, Schrödinger

**3:45 Valentine’s Day Celebration and Poster Competition Winner Announced in the Exhibit Hall (Last Chance to View Posters)**

---

**4:30 Chairperson’s Remarks**
Graeme Sample, Ph.D., Vice President, Discovery Chemistry, Arena Pharmaceuticals, Inc.

**4:35 Meeting Key Challenges in the Discovery of APD811: An Orally Available Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension**
Graeme Sample, Ph.D., Vice President, Discovery Chemistry, Arena Pharmaceuticals, Inc.

**5:05 The New Era of Structure-Based Drug Design GPCRs**

**5:35 Has Fragment Discovery Helped Us Solve the Protein-Protein Interactions Challenge?**
Michelle R. Arkin, Ph.D., Associate Adjunct Professor, Pharmaceutical Chemistry, University of California San Francisco School of Pharmacy

**6:05 Sponsored Presentations (Opportunities Available)**
**6:35 Close of Day**

**FRIDAY, FEBRUARY 15**

**8:00 am Morning Coffee**

**Hot Targets to Watch: Protein-Protein Interactions (cont’d)**

**8:30 Chairperson’s Remarks**
Stephen Hale, Ph.D., Vice President, Drug Discovery, Ensemble Therapeutics

**8:35 Monomeric and Dimeric SMAC Mimetics as Pro-Apoptotic Agents in Anticancer Therapy**
Pierfausto Seneci, Ph.D., Professor, Chemistry, University of Milan

**9:05 The Solution to “Tough-to-Drug” Targets: An Integrated Discovery Engine Leveraging the Unique Properties of Synthetic Macrocycles**
Stephen Hale, Ph.D., Vice President, Drug Discovery, Ensemble Therapeutics

**9:35 Development of Macroyclic Inhibitors against K-Ras Protein**
Speaker to be Announced

**10:05 Sponsored Presentations (Opportunities Available)**

**10:35 Coffee Break**

**Novel Approaches: Phenotypic Screening & Chemical Biology**

**11:00 Development of Isoform Selective Inhibitors of Class I and Class II HDACs for CNS and Metabolic Disorders**
Edward, Holson, Ph.D., Director, Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard

**11:30 Delta-Selective Opioid Agonists for the Treatment of Chronic Pain**
Robin Polt, Ph.D., Professor of Chemistry & Biochemistry, B105, University of Arizona

**12:00 pm Discovery and Optimization of Selective JAK1 Inhibitors as Potential Treatments for Rheumatoid Arthritis**
Mark Zak, Ph.D., Scientist, Discovery Chemistry, Genentech

**12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own**

**Novel Approaches: Medicinal Chemistry Design**

**1:45 Chairperson’s Remarks**
Elizabeth Farrant, Ph.D., Chief Business Officer, Cyclofluidic Ltd

**1:50 Mastering Medicinal Chemistry with Molecular Matched-Pairs**
Jonas Bostrom, Ph.D., Computational Chemist, Medicinal Chemistry, AstraZeneca

**2:20 Generation of Kinase Structure Activity Data Using Integrated Microfluidic Synthesis, Screen and Design**
Elizabeth Farrant, Ph.D., Chief Business Officer, Cyclofluidic Ltd

**2:50 Integrating Flow Chemistry in Drug Discovery**
Noel S. Wilson, Ph.D., Senior Scientist I, Global Pharmaceutical Discovery, Hit to Lead, Abbvie

**3:20 Close of Conference**
Wednesday, February 13

7:00 am Registration and Morning Coffee

Plenary Keynote Session

8:00 Plenary Keynote Presentation (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Biomarkers for Patient Selection and Diagnostics

11:00 Chairperson’s Opening Remarks
Paul Polakis, Ph.D., Director/Staff Scientist, Cancer Targets, Genentech, Inc.

11:10 Featured Presentation: The Yin and Yang of Personalized Medicine
Stefan Scherer, M.D., Ph.D., Vice President, Clinical Development & Medical Affairs, Boehringer Ingelheim Pharma GmbH & Co. KG

Advances with Antibody-Drug Conjugates

11:40 Keynote Presentation: Empowered Antibodies for Cancer Therapy
Peter Senter, Ph.D., Vice President, Chemistry, Seattle Genetics, Inc.

12:10 pm Potent-Payload Linker-Drug Technology – Development of Novel Duocarmycin-Based ADCs
Marco Timmers, Ph.D., CSO, Synthon BV

12:40 Challenges and Successes of Measuring Antigen-Specific T Cell
Magdalena Tary-Lehmann, Ph.D., CSO, Cellular Technology Limited (CTL)

1:45 20th Anniversary Cake in the Exhibit Hall with Poster Viewing

ADCs: Pre-Clinical Development

2:15 Chairperson’s Remarks
Peter Senter, Ph.D., Vice President, Chemistry, Seattle Genetics, Inc.

2:20 Challenges Associated with Research & Development of ADCs
Paul Polakis, Ph.D., Director & Staff Scientist, Cancer Targets, Genentech, Inc.

2:50 Pre-Clinical Development of IMGN529: A Novel CD37-Targeting Antibody-Maytansinoid Conjugate for the Treatment of B-Cell Malignancies
Jutta Deckert, Ph.D., Principal Scientist, Discovery Research, ImmunoGen, Inc.

Thursday, February 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Plenary Keynote Panel (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

ADCs: Pre-Clinical and Clinical Progress

10:40 Chairperson’s Remarks
Alison Betts, Ph.D., Associate Research Fellow, Pharmacokinetics, Dynamics and Metabolism (PDM), Pfizer Worldwide Research & Development

10:45 Anti-Müllerian Inhibiting Substance Type II Receptor Antibodies for Ovarian Cancer Therapy
Gregory P. Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center

11:15 Improvements to ADC Safety with Calicheamicin
Puja Sapra, Ph.D., Director, Oncology Research Unit, Pfizer, Inc.

11:45 Clinical Development of a Novel Auristatin E-Based Antibody Drug Conjugate against SLC44A4 in Resistant Prostate Cancer
Leonard M. Reyno, M.D., Senior Vice President & CMO, Agensys, Inc.

12:15 pm Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

New Targets and Measures to Reach Difficult Targets

1:45 Predictive Drug Discovery for Novel Cancer Biologics
John Hunter, Ph.D., Vice President, Antibody Research & Development, Compugen, Inc.
Approaches Changing the Treatment of Cancer

2:15 Function-Orientated Screening Strategies to Identify Novel and More Effective Cancer Therapeutics
Mary Haak-Frendscho, Ph.D., CEO, Igenica, Inc.

2:45 Proteomics for Trans-Membrane Targets for ADCs
John Terrett, Ph.D., CSO, Oxford Biotherapeutics, Inc.

3:15 Preclinical Development of MGA271, an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity
Claudia Fieger, Ph.D., Scientist, Protein Biochemistry, Macrogenics, Inc.

3:45 Valentine’s Day Celebration and Poster Competition Winner Announced in the Exhibit Hall (Last Chance to View Posters)

Immunotherapy Approaches

4:30 Chairperson’s Remarks
Gregory P. Adams, Ph.D., Co-Leader, Developmental Therapeutics Program, Fox Chase Cancer Center

4:35 Understanding the Role of B Cells in Ovarian Cancer and Implications for Targeted Therapy
Nathalie Scholler, M.D., Ph.D., Assistant Professor, Obstetrics and Gynaecology, Gyn University of Pennsylvania

5:05 Adoptive Therapy of Cancer with Genetically Modified T Cells
Renier J. Brentjens, M.D., Ph.D., Associate Attending Physician, Associate Member, Department of Medicine, Memorial Sloan-Kettering Cancer Center

5:35 Allovectin®: In vivo Studies and Potential Synergy with Other Advanced Melanoma Immunotherapeutics
John Doukas, Ph.D., Senior Director, Pre-Clinical Safety and Efficacy, Vical, Inc.

6:05 Sponsored Presentations (Opportunities Available)

6:35 Close of Day

FRIDAY, FEBRUARY 15

8:00 am Morning Coffee

Bi- and Multi-Specific Antibodies

8:30 Chairperson’s Remarks
Ivan D. Horak, M.D., F.A.C.P., CSO/CMO, R&D, Symphogen A/S

8:35 Improving Potency & Manufacturability of Bi-Specific Antibodies
Jason Baum, Ph.D., Principal Scientist, Research, Merrimack Pharmaceuticals, Inc.

9:05 Multi-Targeting Approaches in Oncology and Angiogenesis by Multi-Specific Darpins
Ulrike Fiedler, Ph.D., Principle Scientist, Disease Biology, Molecular Partners AG

9:35 BiTE® Antibodies for Cancer Therapy
Roman Kischel, M.D., Principal Scientist, BiTE Technology, Amgen Research (Munich) GmbH

10:05 Ang-2-VEGF Crossmab, a Novel Bi-specific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Function
Hubert Kettenberger, Ph.D., Principal Scientist, Pharma Research and Early Development (pRED), Roche Diagnostics GmbH

10:35 Coffee Break

11:00 Targeting Multiple Oncology Sites with Multi-Specific Antibody-Like Molecules
Peter Kiener, Ph.D., President & CEO, Zyngenia, Inc.

11:30 Pre-Clinical Advances with a Fully Human Bispecific Antibody Platform
Eric Smith, Ph.D., Associate Director, Bispecific Antibodies, Regeneron Pharmaceuticals, Inc.

12:00 pm Employing the Bispecific RECRUIT TandAb Platform
Eugene Zhukovsky, Ph.D., CSO, Research, Affimed Therapeutics AG

12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

Combination Therapies

1:45 Chairperson’s Remarks
Ulrike Fiedler, Ph.D., Principle Scientist, Disease Biology, Molecular Partners AG

1:50 Combination Strategies to Enhance Anti-Tumor ADCC
Holbrook Kohrt, M.D., Ph.D., Assistant Professor, Oncology, University of Stanford

2:20 Observations with the ADC Trastuzumab Emtansine (T-DM1) Alone and in Combination
Steve Olsen, M.D., Ph.D., Global Development Team Leader, Trastuzumab Emtansine Product Development-Oncology, Genentech, Inc.

2:50 Novel Strategy to Target Tyrosine Kinase Receptors: From Bench to Clinic
Ivan D. Horak, M.D., F.A.C.P., CSO/CMO, R&D, Symphogen A/S

3:20 Close of Conference

Official Publication: Bio-IT World
WEDNESDAY, FEBRUARY 13

7:00 am Registration and Morning Coffee

Plenary Keynote Session

8:00 Plenary Keynote Presentation (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Strategies to De-Risk Clinical Development

11:00 Chairperson’s Opening Remarks

11:10 Leveraging the Intersection of Mechanism and Disease Biology to De-Risk Early Clinical Development

Scott Kennedy, Ph.D., Global Head, Biomarker Development, Novartis Institutes for BioMedical Research

11:40 Safety of Targeted Immunotherapy in Cancer: Early Toxicity Risk Mitigation Strategies

Rakesh Dixit, Ph.D., Vice President, Research & Development; Global Head, Biologics Safety Assessment, MedImmune

12:10 pm Translating Therapeutic Index into Probability of Success for Clinical Drug Candidates

Patrick Y. Mueller, Ph.D., Director, Global Coordinator, Novartis Institutes for BioMedical Research

12:40 Luncheon Presentation I: A New Method to Rapidly Access “Specificity” of Selected Proteins

Thomas Van Himbergen Ph.D., Content Researcher & Manager, Elsevier

1:10 Luncheon Presentation II: (Sponsorship Opportunity Available) or Lunch on Your Own

1:45 20th Anniversary Cake in the Exhibit Hall with Poster Viewing

Innovation in Clinical Development

2:15 Chairperson’s Remarks

2:20 Human Target Validation and Patient-Centric, Novel Therapeutic Strategies to Improve Clinical Outcomes in R&D

Harsukh Parmar, M.D., Vice President and Head, Translational and Experimental Medicine, F. Hoffmann La Roche

2:50 Innovation in Clinical Trials: Theory vs. Practice

Jorge DiMartino, M.D., Ph.D., Executive Director, Translational Development, Celgene Corp.

3:20 The Difference between Generating and Understanding Research Data: Ontology-Driven Approaches to Advancing Research

Mike Cummens, M.D., CMO, Remedy Informatics

3:50 Sponsored Presentation

Speaker to be Announced

4:05 Establishing Clinically Relevant Biomarkers Through Advanced Single Molecule Counting

Cleland C. Landolt, M.D., CMO, Singulex, Inc.

4:20 Networking Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunities Available)

5:20 Breakout Discussions in the Exhibit Hall (See Web for Details)

6:20 Close of Day

THURSDAY, FEBRUARY 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee

8:00 Plenary Keynote Panel (See Page 2 for Details)

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

Integrating Biomarkers and Genomics into Clinical Development

10:40 Chairperson’s Remarks

10:45 Clinical Trials in Genetically Defined Patient Populations

Jaya Goyal, Ph.D., Principal Investigator, Translational Medicine, Biogen Idec

11:15 From Biomarker to Companion Diagnostic: Different Bumps in Different Roads

Richard Buller, M.D., Ph.D., Vice President, Translational Oncology, Pfizer

11:45 Using Biomarkers in Clinical Trials – Perspectives from the FNIH Biomarkers Consortium

Maria Vassileva, Ph.D., Scientific Program Manager, Metabolic Disorders, The Biomarkers Consortium

12:15 pm Luncheon Presentation I: Metabolomics for Improved Translation through New Targets and Biomarkers

Rob Mohney, Ph.D., Director, Projects (North American Pharma-Biotech), Metabolon, Inc.

12:45 pm Luncheon Presentation II (Sponsorship Opportunity Available) or Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

1:40 Chairperson’s Remarks

1:45 Multifaceted Impact Potential of Biomarkers and Translational Research in Oncology Drug Development

Ronald Linnartz, Senior Director, External Collaborations, Oncology Correlative Sciences, Novartis Pharmaceuticals
Strategies to Accelerate and De-Risk Clinical Development

2:15 Multimodal Dynamic Profiling of Healthy and Diseased States for Personalized Healthcare
George I. Mias, Ph.D., Postdoctoral Scholar, Snyder Lab, Department of Genetics, Stanford University School of Medicine

2:45 Presentation to be Announced

3:15 Translating the Preclinical Pharmacology of the Select TLR8 Agonist VTX-2337, into Clinical Activitusing the Myriad/RBM MAP Inflammation Panel
Gregory N. Dietsch, Ph.D., Vice President, Research, VentiRx Pharmaceuticals

3:30 Sponsored Presentation (Opportunity Available)

3:45 Valentine's Day Celebration and Poster Competition Winner Announced in the Exhibit Hall (Last Chance for Poster Viewing)

Quality of Pre-Clinical Evidence Matters

4:30 Chairperson's Remarks

4:35 Challenges in Translating Pre-Clinical Research into Benefit for Patients: Raising the Bar for Pre-Clinical Cancer Research
C. Glenn Begley, Ph.D., Senior Vice President, TetraLogic

5:05 Building More Predictive in vitro and in vivo Models to Identify Responder Populations Pre-Clinically
Emma Lees, Ph.D., Vice President, Oncology, NIBR Site Head Emeryville, Novartis Institutes for Biomedical Research

5:35 Challenges to Accurately Translating Results from Pre-Clinical Cancer Models to the Clinic
Peter Houghton, Ph.D., Director, Center for Childhood Cancer, Nationwide Children's Hospital

6:05 Sponsored Presentations (Opportunities Available)

6:35 Close of Day

FRIDAY, FEBRUARY 15

8:00 am Morning Coffee

Data Integration Strategies to Support Clinical & Translational Research

8:30 Chairperson's Remarks
Ajay Shah, Ph.D., Director, Research Informatics Division, City of Hope

8:35 Translational Research Informatics Platform at City of Hope
Ajay Shah, Ph.D., Director, Research Informatics Division, City of Hope

9:05 Path to Develop Integrated Data for Biomarker Research
Carol Bova Hill, Ph.D., Informatics Project Leader II, Clinical Research Informatics, Duke Clinical Research Institute

9:35 Data Visualization in Clinical Research
Dimitris Agrafiotis, Janssen R&D, Johnson & Johnson

10:05 Sponsored Presentation
Speaker to be Announced

10:35 Coffee Break

Molecular Profiling for Patient Selection

11:00 Clonal Analysis and Molecular Profiling for Patient Selection
Michael Barrett, Ph.D., Associate Professor, Clinical Translational Research Division; Unit Head, Oncogenomics Laboratory, TGEN

11:30 Molecular Profiling for Patient Selection: MD Anderson Perspective
Apostolia-Maria Tsimberidou, M.D., Ph.D., Associate Professor, Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center

12:00 pm Challenges and Issues in the Clinical Execution of a Biomarker Driven Clinical Trial
Jonathan Cheng, M.D., Director, Oncology Clinical Development, Merck

12:30 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

Clinical Trial Specimens in Cancer Research

1:45 Chairperson's Remarks

1:50 Cooperative Oncology Group Banks (CGBS)
Irina A. Lubensky, M.D., Chief, Resources Development Branch, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH

2:20 The Role of the Biorepository in Cancer Clinical Trials: “From Bed to Bench”
Nilsa C. Ramirez, M.D., Director, Surgical Pathology, Pathology and Laboratory Medicine, Nationwide Children's Hospital; Medical Director, Biopathology Center, Co-I and Lead Pathologist, TCGA BCR, The Research Institute at Nationwide Children's Hospital

2:50 National Breast Cancer Biobank and Oncology Research
Valerie Speirs, Ph.D., Associate Professor, Leeds Institute of Molecular Medicine, University of Leeds

3:20 The Role of the Tissue Bank in Academic Cancer Centers
Teri A. Longacre, M.D., Professor of Pathology, Director, Tissue Procurement Facility, Stanford Cancer Center, Stanford, California

3:50 Close of Conference
**Hotel Information**

Reserve your hotel and save $100 off your conference registration*

*You must book your reservation under the Tri-Conference room block for a minimum of 4 nights at the Marriott or the Intercontinental Hotel. One discount per hotel room.

**Conference Venue:**
The Moscone North Convention Center
747 Howard Street
San Francisco, CA 94103
www.moscone.com

**Host Hotel:**
San Francisco Marriott Marquis
55 Fourth Street
San Francisco, CA 94103
(T) 415-896-1600
Reservations: 888-575-8934
Discounted Group Rate: $229 s/d
Cutoff Date: January 14, 2013

*Room Rate includes complimentary internet access in your guestroom

**Additional Recommended Hotel:**
InterContinental San Francisco Hotel
888 Howard Street
San Francisco, CA 94103
(T) 415-616-6500
Discounted Group Rate: $235 s/d
Cut Off Date: January 14, 2013

Please visit TriConference.com to make your reservations online or call the hotel directly to reserve your sleeping accommodations. You will need to identify yourself as a Molecular Med Tri-Con attendee to receive the discounted room rate with the host hotel. Reservations made after the cut-off date or after the group room block has been filled (whichever comes first) will be accepted on a space- and rate-availability basis. Rooms are limited, so please book early.

**Sponsorship & Exhibit Opportunities**

CHI offers comprehensive sponsorship packages which include presentation opportunities, exhibit space and branding, as well as the use of the pre and post-show delegate lists. Signing on early will allow you to maximize exposure to hard-to-reach decision makers.

**Breakfast & Luncheon Presentations**

Opportunities may include a 15 or 30-minute podium presentation during the main agenda. Boxed lunches are delivered into the main session room, which guarantees audience attendance and participation. Packages include: exhibit space, on-site branding, and more.

**Invitation-Only VIP Dinner/Private Receptions**

Sponsors will select their top prospects from the conference pre-registration list for an evening of networking at the hotel or at a choice local venue. CHI will extend invitations and deliver prospects. Evening will be customized according to sponsor’s objectives.

**Exhibit**

Exhibitors will enjoy facilitated networking opportunities with 3,000 highly-targeted delegates at the overall event. Speak face-to-face with prospective clients and showcase your latest product, service, or solution.

Looking for additional ways to drive leads to your sales team? CHI can help!

We offer clients numerous options for custom lead generation programs to address their marketing and sales needs, including:

- Live Webinars
- White Papers
- Market Surveys
- Podcasts and More!

For sponsorship & exhibit information, please contact:

**Companies A-K**
Jon Stroup, Manager, Business Development
781-972-5483 • jstroup@healthtech.com

**Companies L-Z**
Joseph Vacca, Manager, Business Development
781-972-5431 • jvacca@healthtech.com
Pricing and Registration Information

TRI-CON ALL ACCESS PACKAGE - BEST VALUE! (FEB 11-15)
Includes 1 Symposium or Partnering Forum, 2 Short Courses, and 1 Conference Program.

<table>
<thead>
<tr>
<th>Advance Registration until January 18, 2013</th>
<th>Commercial</th>
<th>Academic, Government, Hospital-affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration after January 18, 2013</td>
<td>$3195</td>
<td>$1845</td>
</tr>
<tr>
<td></td>
<td>$3250</td>
<td>$1930</td>
</tr>
</tbody>
</table>

Regular Pricing – A La Carte Options

PARTNERING FORUM (Monday, Feb 11 – Tuesday, Feb 12)
Emerging Molecular Diagnostics $1450

SYMPOSIA (Monday, Feb 11 – Tuesday, Feb 12)

| S1 Targeting Cancer Stem Cells | Commercial | Academic, Government, Hospital-affiliated |
| S2 Genomics in Medicine        | $1450      | $1025                                    |
| S3 Point-of-Care Diagnostics   | $1450      | $1025                                    |
| S4 Quantitative Real-Time PCR  | $1450      | $1025                                    |
| S5 Next Generation Pathology   | $1450      | $1025                                    |

SHORT COURSES (Tuesday, Feb 12)

<table>
<thead>
<tr>
<th>1 Short Course</th>
<th>Commercial</th>
<th>Academic, Government, Hospital-affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$695</td>
<td>$395</td>
</tr>
<tr>
<td>2 Short Courses</td>
<td>$995</td>
<td>$695</td>
</tr>
</tbody>
</table>

Afternoon

<table>
<thead>
<tr>
<th>SC1 Identification &amp; Characterization of Cancer Stem Cells</th>
<th>Commercial</th>
<th>Academic, Government, Hospital-affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC2 Commercialization Boot Camp: Manual for Success in the Molecular Diagnostics Marketplace</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC3 NGS Data and the Cloud</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC4 Best Practices in Personalized and Translational Medicine</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC5 Latest Advances in Molecular Pathology</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC6 Regulatory Approval of a Therapeutic &amp; Companion Diagnostic: Nuts &amp; Bolts</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC7 PCR Part 1: qPCR in Molecular Diagnostics</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC8 Data Visualization</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC9 Methods for Synthesis &amp; Screening of Macrocyclic Compound Libraries</td>
<td>$1450</td>
<td>$1025</td>
</tr>
</tbody>
</table>

Dinner

<table>
<thead>
<tr>
<th>SC10 PCR Part II: Digital PCR Applications and Advances</th>
<th>Commercial</th>
<th>Academic, Government, Hospital-affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC11 Sample Prep and Biorepositories for Cancer Research</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC12 Next-Generation Sequencing in Molecular Pathology: Challenges and Applications</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC13 Strategies for Companion Diagnostics Development</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC14 Patient-Derived Cancer Tissue Xenograph Models</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC16 Microfluidics Technology and Market Trends</td>
<td>$1450</td>
<td>$1025</td>
</tr>
<tr>
<td>SC17 Open Cloud &amp; Data Science</td>
<td>$1450</td>
<td>$1025</td>
</tr>
</tbody>
</table>

CONFERENCE PROGRAMS (Wednesday, Feb 13 - Friday, Feb 15)

<table>
<thead>
<tr>
<th>Advance Registration until January 18, 2013</th>
<th>Commercial</th>
<th>Academic, Government, Hospital-affiliated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration after January 18, 2013</td>
<td>$2345</td>
<td>$1245</td>
</tr>
</tbody>
</table>

Diagnostics Channel

| P1 Molecular Diagnostics                      | Commercial | Academic, Government, Hospital-affiliated |
| P2 Personalized Diagnostics                   | $1450      | $1025                                    |
| P3 Cancer Molecular Markers                   | $1450      | $1025                                    |
| P4 Circulating Tumor Cells                    | $1450      | $1025                                    |
| P5 Digital Pathology – NEW                    | $1450      | $1025                                    |
| P6 Companion Diagnostics – NEW                | $1450      | $1025                                    |

Therapeutics Channel

| P7 Mastering Medicinal Chemistry Summit       | Commercial | Academic, Government, Hospital-affiliated |
| P9 Cancer Biologics                           | $1450      | $1025                                    |
| P11 Clinical and Translational Science        | $1450      | $1025                                    |

Clinical Channel

| P10 Oncology Clinical Trials                  | Commercial | Academic, Government, Hospital-affiliated |
| P11 Clinical and Translational Science        | $1450      | $1025                                    |

Informatics Channel

| P13 Bioinformatics                            | Commercial | Academic, Government, Hospital-affiliated |
| P14 Integrated R&D Informatics & Knowledge Management | $1450      | $1025                                    |

Cancer Channel

| P3 Cancer Molecular Markers                   | Commercial | Academic, Government, Hospital-affiliated |
| P4 Circulating Tumor Cells                    | $1450      | $1025                                    |
| P5 Predictive Pre-Clinical Models in Oncology – NEW | $1450      | $1025                                    |
| P10 Oncology Clinical Trials                  | $1450      | $1025                                    |

CONFERENCE DISCOUNTS

Poster ($50 Off)  Alumni (20% Off)  BayBio (20% Off)
*Alumni and BayBio Discount cannot be combined. Discounts not applicable on Event Short Courses.

Alumni Discount SAVE 20%: We appreciate your past participation at the Molecular Med TRI-CON. Through loyalty like yours, this event has become a must-attend for senior level decision makers. As a result of your great loyalty, we are pleased to extend this exclusive opportunity to save an additional 20% off the registration rate.

Hotel Discount ($100 Off): Reserve your hotel and save $100 OFF your conference registration. *You must book your reservation under the Tri-Conference room block for a minimum of 4 nights.

Poster Submission: Discount ($50 Off) Dedicated poster sessions for Symposia and Conference Programs. Present your poster at both!** Poster abstracts are due by December 21, 2012. Once your registration has been fully processed, we will send an email containing a unique link allowing you to submit your poster abstract. If you do not receive your link within 5 business days, please contact jring@healthtech.com.
** One poster discount per registration.

Register 3 - 4th is FREE: Individuals must register for the same conference or conference combination and submit completed registration form together for discount to apply. Additional discounts are available for multiple attendees from the same organization. For more information on group rates contact David Cunningham at +1-781-972-5472

Please use keycode DDD F when registering!

How to Register: TriConference.com/Therapeutics
reg@healthtech.com • P: 781.972.5400 or Toll-free in the U.S. 888.999.6288